Every Form 4 that Nutex Health Inc (NUTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NUTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUTX filings page.
Nutex Health Inc. director Frank E. Jaumot reported acquiring 603 shares of Common Stock on July 31, 2026 through the exercise or conversion of a derivative security. A related footnote explains that restricted stock units convert into common stock on a one-for-one basis. After this transaction, he directly owns 753 shares.
Nutex Health Inc. director Cheryl Yvonne Grenas reported the exercise and conversion of restricted stock units into 603 shares of common stock on July 31, 2026. The units convert into common stock on a one-for-one basis and were recorded at $0.0000 per share, bringing her direct holdings to 670 shares after the transaction.
Nutex Health Inc. director Scott J. Saunders acquired 603 shares of common stock on 2026-07-31 through the conversion of restricted stock units, which convert into common stock on a one-for-one basis. The shares were acquired at $0.0000 per share and are held directly, totaling 603 shares.
Nutex Health director Michael Lee Reed reported the conversion of restricted stock units into 603 shares of Common Stock on July 31, 2026, at a stated price of $0.0000 per share. The shares are held indirectly through the Michael L Reed Trust IRA (MLRTIRA), bringing his reported indirect holdings to 670 shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Nutex Health Inc. reported that director Kelvin Spears received 2,519 shares of common stock in a private, non-market transaction. The issuance relates to one-time obligations tied to his pro-rata share of an under-construction hospital transferred under a 2021 merger agreement, bringing his direct holdings to 34,656 shares.
Nutex Health Inc. director and CEO Thomas T. Vo reported an "other" Form 4 transaction involving 75,747 shares of common stock held indirectly through Micro Hospital Holdings LLC. The shares were issued in a private transaction to satisfy one-time obligations tied to two under-construction hospitals.
Following this restructuring-related issuance, Micro Hospital Holdings LLC is shown as holding 2,103,014 Nutex Health common shares indirectly for Vo, who owns and controls the LLC.
Reed Michael Lee reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Michael Lee received a grant of 823 Restricted Stock Units (RSUs) as equity compensation. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest 100% on April 23, 2027, with pro-rata vesting if he leaves the company without cause during the vesting period. Following this award, Lee holds a total of 1,426 RSUs directly. This filing reflects a compensation-related stock unit grant, not an open-market share purchase or sale.
Saunders Scott J reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Scott J. Saunders received a grant of 823 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Nutex common stock upon vesting. These RSUs vest 100% on April 23, 2027, and will vest on a pro-rata basis if he leaves the company without cause before that date. Following this award, Saunders holds a total of 1,426 RSUs directly.
Nutex Health Inc. director Frank E. Jaumot received a grant of 823 Restricted Stock Units (RSUs) on April 23, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of common stock upon vesting. These RSUs vest 100% on April 23, 2027, with pro‑rata vesting if he leaves the company without cause during the vesting period. Following this award, Jaumot holds 1,426 RSUs directly. This is a compensation-related acquisition, not an open‑market stock purchase or sale.
Grenas Cheryl Yvonne reported acquisition or exercise transactions in this Form 4 filing.
Nutex Health Inc. director Cheryl Yvonne Grenas received a grant of 823 Restricted Stock Units (RSUs), each representing one share of common stock upon vesting. The RSUs vest 100% on April 23, 2027, with pro-rata vesting if she leaves the company without cause before that date. Following this award, she holds 1,426 RSUs directly.
Nutex Health Inc. director and CEO Thomas T. Vo reported two insider equity transactions. First, an entity he owns and controls, Micro Hospital Holdings LLC, received 184,071 shares of common stock in a private issuance. These shares relate to Vo’s pro-rata interest in two under-construction hospitals previously transferred to Nutex Health Holdco LLC under an Agreement and Plan of Merger. Following this issuance, Micro Hospital Holdings LLC holds 2,027,267 common shares indirectly for Vo.
Separately, Vo exercised 4,841 restricted stock units (RSUs) into an equal number of common shares at a stated price of $0.00 per share, with 16,507 RSUs shown as beneficially owned afterward. The Form 4 also corrects the previously reported RSU balance from an earlier filing.
Nutex Health Inc. reported that Chief Operating Officer Wesley Shane Bamburg acquired 2,411 restricted stock units (RSUs) on March 11, 2026 as equity compensation. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, aligning Bamburg’s incentives with the company’s long-term performance rather than reflecting any open-market share purchase or sale.
Nutex Health Inc. director and president Warren Hosseinion reported two equity-related moves. On March 19, 2026 he made an open-market purchase of 252 shares of common stock at a price of $94.0723 per share, bringing his direct common stock holdings to 7,765 shares.
On March 10, 2026 he also exercised 3,656 restricted stock units into an equivalent number of common shares, a derivative exercise recorded at a conversion price of $0.00 per unit, with 12,465 restricted stock units beneficially owned following that grant. A footnote explains this Form 4 corrects the previously reported RSU balance from an earlier filing for that March 10 transaction.
Nutex Health Inc. director Frank E. Jaumot bought 150 shares of common stock in an open-market purchase. The transaction took place on March 20, 2026 at a price of $93.555 per share. After this trade, he directly holds 150 Nutex Health shares.
Nutex Health director Kelvin Spears reported a small open-market share purchase and an RSU-related stock acquisition. The filing also corrects his previously reported RSU holdings.
On March 17, 2026 he bought 10 common shares at $94.46, bringing his direct stake to 32,137 shares. A March 10, 2026 derivative transaction converted 116 restricted stock units into common stock, and 339 RSUs are now reported as beneficially owned following the correction.
Nutex Health Inc. Chief Legal Officer-Healthcare Pamela W. Montgomery reported acquiring additional equity in the company. She made an open-market purchase of 79 shares of common stock at a price of $88.8699 per share, bringing her directly held common stock position to 2,758 shares.
She also exercised a derivative position in the form of 1,523 restricted stock units, converting them into an equivalent common stock interest at a stated exercise price of $0.00, with 4,441 restricted stock units beneficially owned following this transaction. A footnote explains that this filing corrects the previously reported number of restricted stock units from an earlier Form 4 relating to the March 10, 2026 RSU grant.
Nutex Health Inc. Chief Legal Officer Luqman Elisa V reported routine equity compensation activity involving restricted stock units and common stock. Restricted stock units convert into common stock on a one-for-one basis, and the officer held 4,441 such units following the reported transaction.
Subsequent to vesting, 2,084 common shares were issued, of which 784 shares were delivered to satisfy tax withholding obligations, leaving the remainder as net shares. After these movements, the officer beneficially owned 2,370 common shares, including 2,360 shares held directly and 10 shares held indirectly through a spouse.
Nutex Health Inc. Chief Legal Officer-Healthcare Pamela W. Montgomery reported routine equity compensation activity. She exercised restricted stock units that convert into common stock on a one-for-one basis, resulting in the issuance of 2,084 shares of common stock, of which 776 shares were delivered to cover tax withholding obligations.
After these transactions, Montgomery directly held 2,679 shares of common stock. She was also granted 1,525 restricted stock units on March 11, 2026, scheduled to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Nutex Health Inc. director Kelvin Spears reported compensation-related stock activity. He received 183 shares of common stock upon vesting of previously granted restricted stock units, with 82 of those shares withheld to cover tax obligations, leaving a net 101 new shares and bringing his direct common stock holdings to 32,127 shares.
He was also granted 116 new restricted stock units that each convert into one share of common stock and are scheduled to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. These transactions are routine equity compensation events rather than open-market purchases or sales.
Nutex Health Inc. Chief Medical Officer Michael L. Chang reported equity compensation and related tax withholding transactions. On March 10, 2026, he was granted 1,936 restricted stock units (RSUs), which will vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029. A related entry shows 2,084 common shares issued subsequent to vesting, with 769 shares delivered to cover tax withholding obligations at an indicated value of $86.2224 per share, a non‑market disposition that does not represent an open‑market sale. Following these transactions, Michael Chang PLLC directly holds 82,356 common shares, and Dr. Chang directly owns an additional 984 shares, reflecting ongoing equity alignment through both direct and indirect holdings.
Nutex Health Inc. president Warren Hosseinion reported routine equity compensation activity. He exercised 3,656 restricted stock units, which convert into common stock on a one-for-one basis, and received 6,293 common shares upon vesting. Of those shares, 3,274 were delivered at a price of 86.2224 per share to cover tax withholding obligations. Following these transactions, he holds 7,513 shares of common stock directly and 15,739 restricted stock units that remain outstanding and unexercised, which are scheduled to vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Nutex Health Inc. CEO Thomas T. Vo reported routine equity compensation activity involving restricted stock units and common shares. Previously granted RSUs converted into 8,334 shares of common stock, and 3,017 of those shares were delivered to satisfy tax withholding obligations rather than sold in an open-market trade.
After these transactions, entities he owns and controls held 1,843,196 common shares, and his direct holdings included 19,524 restricted stock units. He was also granted 4,841 new RSUs that vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Nutex Health Inc. Chief Financial Officer Jon Christian Bates reported compensation-related equity activity. He acquired 2,667 shares of common stock through a derivative exercise, bringing his direct common stock holdings to 8,305 shares. He was also granted 1,694 restricted stock units, which convert into common stock on a one-for-one basis and vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029, increasing his restricted stock unit balance to 5,527 units. These transactions reflect equity compensation and derivative exercises, not open-market buying or selling.
Nutex Health, Inc. director Scott J. Saunders reported receiving an equity award in the form of restricted stock units. On July 14, 2025, he was granted 603 RSUs at a price of $0 per unit, each representing the right to receive one share of Nutex common stock upon vesting.
These RSUs vest 100% on July 14, 2026. If Saunders leaves the company without cause before that vesting date, the award will vest on a pro-rata basis according to the actual time he remained in service with the company.
Nutex Health, Inc. director Michael Lee Reed received an equity grant of 603 restricted stock units (RSUs) on July 14, 2025. Each RSU represents the right to receive one share of Nutex common stock with $0.001 par value upon vesting, for no cash exercise price.
The 603 RSUs are scheduled to vest 100% on July 14, 2026. If Reed leaves the company without cause before that date, the RSUs will vest on a pro-rata basis according to his actual time in service during the vesting period. After this grant, Reed beneficially owns 603 RSUs directly.
Nutex Health, Inc. director Cheryl Yvonne Grenas reported an equity award in the form of 603 restricted stock units (RSUs) on July 14, 2025. Each RSU represents the right to receive one share of Nutex common stock upon vesting. These RSUs vest 100% on July 14, 2026, with a provision that if she leaves the company without cause during the vesting period, the award will vest on a pro-rata basis based on her actual time in service.
Nutex Health director Frank E. Jaumot reported receiving a grant of 603 restricted stock units (RSUs) of Nutex Health, Inc. common stock. The RSUs were granted on July 14, 2025 at an exercise price of $0 and are held directly.
Each RSU represents the right to receive one share of Nutex Health common stock upon vesting. The grant vests 100% on July 14, 2026, with a provision for pro-rata vesting based on time served if Jaumot leaves the company without cause during the vesting period.